Mufemilast
Mufemilast[edit | edit source]
Mufemilast is a pharmaceutical drug that acts as a phosphodiesterase-4 (PDE4) inhibitor. It is primarily being investigated for its potential use in treating various inflammatory conditions, including chronic obstructive pulmonary disease (COPD) and psoriasis.
Mechanism of Action[edit | edit source]
Mufemilast works by inhibiting the enzyme phosphodiesterase-4 (PDE4), which is involved in the breakdown of cyclic adenosine monophosphate (cAMP) in cells. By preventing the degradation of cAMP, mufemilast increases its levels within cells. Elevated cAMP levels lead to a reduction in the release of pro-inflammatory cytokines and other mediators of inflammation, thereby exerting an anti-inflammatory effect.
Clinical Applications[edit | edit source]
Chronic Obstructive Pulmonary Disease (COPD)[edit | edit source]
Mufemilast is being studied for its potential to treat COPD, a chronic inflammatory lung disease that causes obstructed airflow from the lungs. By reducing inflammation, mufemilast may help improve lung function and reduce the frequency of COPD exacerbations.
Psoriasis[edit | edit source]
Psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells leading to scaling and inflammation. Mufemilast's anti-inflammatory properties make it a candidate for reducing the symptoms of psoriasis, such as redness and scaling.
Pharmacokinetics[edit | edit source]
Mufemilast is administered orally. After administration, it is absorbed into the bloodstream and distributed throughout the body. The drug is metabolized primarily in the liver and excreted through the kidneys. The pharmacokinetic profile of mufemilast supports its use in chronic conditions where long-term treatment is necessary.
Side Effects[edit | edit source]
Common side effects of mufemilast may include gastrointestinal disturbances such as nausea and diarrhea, as well as headaches. As with other PDE4 inhibitors, there is a potential for psychiatric side effects, including anxiety and depression, which should be monitored during treatment.
Development and Research[edit | edit source]
Mufemilast is currently undergoing clinical trials to evaluate its efficacy and safety in various inflammatory conditions. Ongoing research aims to better understand its therapeutic potential and to optimize its use in clinical practice.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
